Cargando…

Assessing the quality of life of patients with metastatic castration-resistant prostate cancer with bone metastases receiving [(223)Ra]RaCl(2) therapy

[(223)Ra]RaCl(2) dichloride treatment in patients with metastatic castration-resistant prostate cancer (mCRPC) is associated with improved overall survival (OS) and a delay in the time to the first symptomatic skeletal-related event. The aim of this study was to evaluate the quality of life (QoL) of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sraieb, Miriam, Hirmas, Nader, Conrad, Rupert, Marinova, Milka, Essler, Markus, Herrmann, Ken, Ahmadzadehfar, Hojjat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	5700
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7505355/ https://www.ncbi.nlm.nih.gov/pubmed/32957385 http://dx.doi.org/10.1097/MD.0000000000022287

Ejemplares similares

Comparing absorbed doses and radiation risk of the α-emitting bone-seekers [(223)Ra]RaCl(2) and [(224)Ra]RaCl(2)
por: Lassmann, Michael, et al.
Publicado: (2023)

[(223)Ra] RaCl(2) nanomicelles showed potent effect against osteosarcoma: targeted alpha therapy in the nanotechnology era
por: Yang, Yang, et al.
Publicado: (2022)

Ultrastructural Analysis of Cancer Cells Treated with the Radiopharmaceutical Radium Dichloride ([(223)Ra]RaCl(2)): Understanding the Effect on Cell Structure
por: Diniz Filho, Joel Félix Silva, et al.
Publicado: (2023)

α-Particle-induced DNA damage tracks in peripheral blood mononuclear cells of [(223)Ra]RaCl(2)-treated prostate cancer patients
por: Schumann, S., et al.
Publicado: (2021)

Quantitative measurement of (219)Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with (223)RaCl(2)
por: Ooe, Kazuhiro, et al.
Publicado: (2019)

Scintigraphic Load of Bone Disease Evaluated by DASciS Software as a Survival Predictor in Metastatic Castration-resistant Prostate Cancer Patients Candidates to 223RaCl Treatment
por: Frantellizzi, Viviana, et al.
Publicado: (2019)

Nanomicelles of Radium Dichloride [(223)Ra]RaCl(2) Co-Loaded with Radioactive Gold [(198)Au]Au Nanoparticles for Targeted Alpha–Beta Radionuclide Therapy of Osteosarcoma
por: Souza, Bárbara Nayane Rosário Fernandes, et al.
Publicado: (2022)

Pain Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with (223)Ra: PARABO, a Prospective, Noninterventional Study
por: Palmedo, Holger, et al.
Publicado: (2023)

The DASciS Software for BSI Calculation as a Valuable Prognostic Tool in mCRPC Treated with 223RaCl2: A Multicenter Italian Study
por: De Feo, Maria Silvia, et al.
Publicado: (2023)

Ra223 in Bone Metastases with Osteolytic Activity
por: Costa, Renato Patrizio, et al.
Publicado: (2018)

Radioligand therapy of metastatic prostate cancer using (177)Lu-PSMA-617 after radiation exposure to (223)Ra-dichloride
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2017)

Ra-223 Treatment for Bone Metastases in Castrate-Resistant Prostate Cancer: Practical Management Issues for Patient Selection
por: Den, Robert B., et al.
Publicado: (2019)

Fine Structures in $^{14}C$ Emission of $^{223}Ra$ and $^{224}Ra$
por: Hourani, E, et al.
Publicado: (1991)

Laser isotope separation of (223)Ra
por: Suryanarayana, M. V.
Publicado: (2023)

Fine structure in 14C emission from 223Ra and 224Ra
por: Hourani, E, et al.
Publicado: (1991)

Temperature effects on alpha radioactivity of $^{223}$Ra
por: Huber, Gerhard, et al.
Publicado: (2006)

Response to (223)Ra-dichloride in castration-resistant prostate cancer with bone metastasis: A case report
por: Cabrera, Montserrat Estorch, et al.
Publicado: (2016)

Radioligand therapy of metastatic castration-resistant prostate cancer: current approaches
por: Awang, Zool Hilmi, et al.
Publicado: (2018)

(177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior (223)Ra (RALU Study)
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Submarine groundwater discharge data at meter scale ((223)Ra, (224)Ra, (226)Ra, (228)Ra and (222)Rn) in Indian River Bay (Delaware, US)
por: Duque, Carlos, et al.
Publicado: (2019)

Radiopharmacokinetic modelling and radiation dose assessment of (223)Ra used for treatment of metastatic castration-resistant prostate cancer
por: Höllriegl, Vera, et al.
Publicado: (2021)

(223)Ra-Dichloride in castration-resistant metastatic prostate cancer: improving outcomes and identifying predictors of survival in clinical practice
por: Dizdarevic, Sabina, et al.
Publicado: (2018)

$^{223}$Ra nuclear spectroscopy in $^{14}$C cluster radioactivity
por: Hourany, E, et al.
Publicado: (1995)

Radiobiological effects of the alpha emitter Ra-223 on tumor cells
por: Bannik, Kristina, et al.
Publicado: (2019)

Dosimetry-Based Consideration on Remission and Relapse after Therapy with (223)Ra-Dichloride in Castration-Resistant Prostate Cancer (CRPC) with Bone Metastases. A Case Report
por: Mangano, Anna Maria, et al.
Publicado: (2018)

(177)Lu-Prostate-Specific Membrane Antigen Ligand After (223)Ra Treatment in Men with Bone-Metastatic Castration-Resistant Prostate Cancer: Real-World Clinical Experience
por: Sartor, Oliver, et al.
Publicado: (2022)

Safety and Survival Outcomes of (177)Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior (223)Ra treatment: The RALU Study
por: Rahbar, Kambiz, et al.
Publicado: (2023)

Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

Improved (223)Ra Therapy with Combination Epithelial Sodium Channel Blockade
por: Abou, Diane S., et al.
Publicado: (2021)

Prognostic Value of the BIO-Ra Score in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223 after the European Medicines Agency Restricted Use: Secondary Investigations of the Multicentric BIO-Ra Study
por: Bauckneht, Matteo, et al.
Publicado: (2022)

Precise study of fine structure in $^{14}$C emission from $^{223}$Ra
por: Hourani, E, et al.
Publicado: (1992)

Revision of the NIST Standard for (223)Ra: New Measurements and Review of 2008 Data
por: Zimmerman, B. E., et al.
Publicado: (2015)

(223)Ra-dichloride therapy of bone metastasis: optimization of SPECT images for quantification
por: Benabdallah, Nadia, et al.
Publicado: (2019)

(18)F-fluoride PET: changes in uptake as a method to assess response in bone metastases from castrate-resistant prostate cancer patients treated with (223)Ra-chloride (Alpharadin)
por: Cook, Gary JR, et al.
Publicado: (2011)

The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with (223)Ra: first in human study
por: Sciuto, Rosa, et al.
Publicado: (2021)

The prognostic power of inflammatory indices and clinical factors in metastatic castration-resistant prostate cancer patients treated with radium-223 (BIO-Ra study)
por: Bauckneht, Matteo, et al.
Publicado: (2021)

Precise study of fine structure in $^{14}$C emission from $^{223}$Ra: Rev
por: Hourani, E, et al.
Publicado: (1992)

Determination, Modeling and Evaluation of Kinetics of (223)Ra Sorption on Hydroxyapatite and Titanium Dioxide Nanoparticles
por: Suchánková, Petra, et al.
Publicado: (2020)

Author Correction: Pretreatment PSA levels affects the completion rate of Ra-223 treatment
por: Utsumi, Nobuko, et al.
Publicado: (2021)

It is time to move forward into the era of Theranostics
por: Ahmadzadehfar, Hojjat, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_rd6lrfr2gvkp9ep44q3vlld9r6